文献速递肿瘤 PET/CT核素与放射性配体治疗

生长抑素受体PET的正常变异、陷阱与判读挑战

Normal variants, pitfalls, and interpretation challenges of somatostatin receptor PET.
PubMed 文献 · Semin Nucl Med · 2026-10-24

本文综述生长抑素受体(SSTR)PET在神经内分泌肿瘤(NET)应用中的生理性变异、假阳性和假阴性表现,并讨论生物分布、受体异质性、定量判读及诊疗一体化决策中的当代陷阱。准确判读需整合分子、解剖和临床信息,而非依赖孤立摄取值或二元阳性/阴性分类。

要点

  • 生理性SSTR表达、局灶性变异、技术伪影及炎症或非神经内分泌病变可模拟NET摄取。
  • 病灶小、部分容积效应、高生理背景及低/无受体表达可致假阴性或低估。
  • 生长抑素类似物治疗可改变正常器官生物分布和病灶-背景对比,肝脾摄取在系列检查间可大幅变化。

核心结论

  • SSTR PET判读需整合分子、解剖和临床信息,不能仅凭孤立摄取值或二元阳性/阴性分类。

研究设计与样本

  • 综述,总结SSTR PET的主要生理性变异及假阳性和假阴性表现。

主要发现

  • 生理性SSTR表达、局灶性正常生物分布变异、技术与给药相关伪影、炎症及良恶性非神经内分泌病变均可产生模拟NET的摄取。
  • 小病灶、部分容积效应、高生理背景及真正低或无受体表达可降低病灶可见性,导致假阴性或疾病低估。
  • 生长抑素类似物治疗可改变正常器官生物分布和病灶-背景对比,肝脾摄取在系列检查间可大幅变化,不应视为稳定参考组织。
  • 病灶间受体表达差异在SSTR PET评估PRRT适用性时有实际意义,部分病灶高摄取不必然代表所有临床相关病灶靶表达充分。

临床怎么用

  • 判读SSTR PET时应结合分子、解剖和临床信息,避免仅依赖孤立摄取值或二元阳性/阴性分类。
  • 评估PRRT适用性时需考虑病灶间受体表达异质性,不应以部分病灶高摄取推断全部病灶靶表达充分。
  • 系列检查中肝脾摄取可大幅变化,不应默认其为稳定参考组织。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatostatin receptor (SSTR) PET has become a central imaging tool in neuroendocrine tumors (NETs), with established roles in detection, staging, restaging, and selection of patients for peptide receptor radionuclide therapy (PRRT). Despite its high sensitivity and target specificity, interpretation is not always straightforward. Physiological SSTR expression, focal variants of normal biodistribution, technical and administration-related artifacts, inflammatory conditions, and benign or malignant non-neuroendocrine lesions may all generate uptake that mimics NET involvement. Conversely, small lesion size, partial-volume effects, high physiological background, and genuinely low or absent receptor expression may reduce lesion conspicuity and lead to false-negative or underestimated disease. Interpretive challenges have also become more relevant as SSTR PET is increasingly used for quantitative, longitudinal, and theranostic assessment. Somatostatin analogue treatment can modify normal-organ biodistribution and lesion-to-background contrast, while liver and spleen uptake may vary substantially across serial examinations and should not necessarily be considered stable reference tissues. In addition, inter-lesional differences in receptor expression may have practical implications when SSTR PET is used to assess suitability for PRRT, because intense uptake in part of the disease does not necessarily imply adequate target expression across all clinically relevant lesions. This review summarizes the principal physiological variants and false-positive and false-negative findings encountered on SSTR PET and discusses contemporary pitfalls related to biodistribution, receptor heterogeneity, quantitative interpretation, and theranostic decision-making. Accurate interpretation requires integration of molecular, anatomical, and clinical information rather than reliance on isolated uptake intensity or a binary positive/negative classification.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Imperiale A, Mouissi I, Huon M, et al. Normal variants, pitfalls, and interpretation challenges of somatostatin receptor PET. Semin Nucl Med. 2026. PMID: 42926166. doi:10.1053/j.semnuclmed.2026.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。